BioHarvest Sciences Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ilan Sobel
- Full Time Employees
- 87
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Address
- 1140-625 Howe Street Vancouver BC Canada V6C 2T6
- IPO Date
- Jan 8, 2021
- CIK
- 0001723464
- Website
- bioharvest.com
- Similar Companies
- Business
- BioHarvest Sciences Inc. operates as a biotechnology company specializing in botanical synthesis technology. The company develops and owns a patented bio-cell growth platform that produces plant-based compounds without the need to grow the underlying plants. Its core products and services span two main verticals: nutraceutical health and wellness products, including dietary supplements such as the VINIA red grape cell product containing polyphenols like Piceid resveratrol, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) targeting specific medical indications. Additionally, BioHarvest offers contract development and manufacturing services for clients seeking novel plant-based molecules. The company’s botanical synthesis platform enables large-scale, consistent production of plant metabolites with a lower environmental footprint compared to traditional agriculture and extraction methods. BioHarvest operates primarily in the United States and Israel, with headquarters in Vancouver, Canada, and was founded in 2007. Recently, BioHarvest Sciences has expanded its U.S. market presence with the launch of VINIA Blood Flow Hydration™, the first hydration product leveraging the blood flow benefits of VINIA’s Piceid resveratrol within the $13 billion U.S. electrolyte drink market. The company announced an upsized public offering raising approximately $19.9 million in gross proceeds to strengthen its balance sheet and support growth initiatives. In late 2024, BioHarvest entered a strategic partnership with Tate & Lyle PLC to develop next-generation plant-based ingredient solutions for food and beverages, reflecting a broader strategic focus on sustainable, clinically validated botanical products. Operationally, the company is advancing new botanical compositions based on plant cells from sources such as olives and pomegranates to further expand its nutraceutical and pharmaceutical pipeline. The company strictly adheres to high regulatory and quality standards including ISO and GMP certifications to support scientific and clinical rigor in its products and services. BioHarvest Sciences serves an evolving global market of health-conscious consumers and pharmaceutical clients seeking innovative, plant-based therapeutic solutions that are sustainably sourced and scientifically validated.
BioHarvest Sciences and Tate & Lyle expand sweetener development program
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences Q1 Earnings Call Highlights
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
Alibaba shares jump as AI cloud surge offsets mixed quarterly results
BioHarvest Sciences wins $1.2M fragrance contract
Plug Power reports first quarter earnings beat on narrower losses, margins progress
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Will BioHarvest Sciences Inc. (BHST) Report Negative Earnings Next Week? What You Should Know
BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
Alphabet tops quarterly revenue and profit estimates on Google Cloud surge
BioHarvest Sciences names co-founder Rakib as CEO in leadership transition
BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy
GE HealthCare shares tumble after profit miss and guidance cut